CYP19A1 and breast cancer: As shown with anti-oestrogens [17], these data are consistent with the hypothesis that aromatase inhibitors such as letrozole induce regression of breast cancer in vivo by simply blocking progression of cells through the cell cycle rather than by a direct cytotoxic effect.